
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.

NeosRx CEO Jeff Dunn, Pharm.D., MBA, explains how 340B claims can disadvantage PBMs because of loss of rebates..

Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.

Drug launch prices are rising, but Benjamin N. Rome, M.D., M.P.H., and colleagues found no evidence manufacturers raised them in response to the Inflation Reduction Act.

DPP-1 inhibitors are oral small molecules that block the enzyme responsible for activating neutrophil elastase, and in the pivotal ASPEN trial, brensocatib reduced annualized exacerbations by about 20% versus placebo.

DPP-1 inhibitors are oral small molecules that block the enzyme responsible for activating neutrophil elastase, and in the pivotal ASPEN trial, brensocatib reduced annualized exacerbations by about 20% versus placebo.

Naik says a strong recommendation for infliximab and a call for routine pain assessment are the HS guideline changes most likely to change clinical practice.

New guidelines for care of hidradenitis suppurativa advise against radiotherapy for children and adolescents, citing its long-term risks and safer treatment options.

Hidradenitis suppurativa was long thought to be a rare condition, but global data put the prevalence at 1%, says Naik, co-chair of the new AAD-HS Foundation guidelines for the disease.




